ICNMD 2024

Confirmed Sponsors - ICNMDigital 2023

ICNMDigital 2023 would like to thank the following companies for their support:

Diamond Sponsor

PTC Therapeutics is a science-driven, global biopharmaceutical company focused on the discovery and development of clinically differentiated medicines that provide benefits to patients with rare disorders. Our mission is to provide access to best-in-class treatments for patients with little to no treatment options. (www.ptcbio.com)

Gold Sponsors

Novartis Gene Therapies is reimagining medicine to transform the lives of people living with rare genetic diseases. Utilizing cutting-edge technology, we are working to turn promising gene therapies into proven treatments. We are powered by an extensive manufacturing footprint, in capacity and expertise, enabling us to bring gene therapy to patients around the world at quality and scale. Novartis Gene Therapies OAV101 clinical development program represents a growing body of research in a range of patients with SMA, across ages, SMA types and incident and prevalent populations, investigating both intravenous and intrathecal formulations. (www.novartis.com)

Grifols is a leading global healthcare company founded in Barcelona in 1909 that develops and provides plasma-derived medicines and other innovative biopharmaceuticals to enable millions of patients around the world to lead more productive lives. The company provides its innovative healthcare solutions and services in more than 110 countries and regions. (www.grifols.com)

Silver Sponsors

Sarepta Therapeutics is on an urgent mission: engineer precision genetic  medicine for rare diseases that devastate lives and cut futures short. Our focus is on Duchenne and limb-girdle muscular dystrophies, and we have 40+ programs in development across 3 technologies – gene therapy, RNA and gene editing. (www.sarepta.com)

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company committed to developing and commercializing innovative medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. We are focusing on the development of treatments for neuromuscular and pulmonary diseases that currently lack treatment options, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF) and have dedicated more than a decade to researching potential treatments in our ongoing mission to make effective medicines available for these often overlooked, life-altering diseases. (www.santhera.com)